First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer

por Su, Po‐Lan, Chen, Chian‐Wei, Wu, Yi‐Lin, Lin, Chien‐Chung, Su, Wu‐Chou
Publicado 2020

Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study

por Huang, Tang-Hsiu, Kuo, Chin-Wei, Chen, Chian-Wei, Tseng, Yau-Lin, Wu, Chao-Liang, Lin, Sheng-Hsiang
Publicado 2021

Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study

por Huang, Tang-Hsiu, Kuo, Chin-Wei, Chen, Chian-Wei, Tseng, Yau-Lin, Wu, Chao-Liang, Lin, Sheng-Hsiang
Publicado 2021

Navigating the challenges of invasive pulmonary aspergillosis in lung cancer treatment: a propensity score study

por Kuo, Chin-Wei, Lin, Chien-Yu, Wei, Sheng-Huan, Chou, Yun-Tse, Chen, Chian-Wei, Tsai, Jeng-Shiuan, Su, Po-Lan, Lin, Chien-Chung
Publicado 2023

Development and validation of a prediction index for recent mortality in advanced COPD patients

por Tsai, Sheng-Han, Shih, Chia-Yin, Kuo, Chin-Wei, Liao, Xin-Min, Lin, Peng-Chan, Chen, Chian-Wei, Hsiue, Tzuen-Ren, Chen, Chiung-Zuei
Publicado 2022

Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio

por Tsai, Jeng-Shiuan, Wei, Sheng-Huan, Chen, Chian-Wei, Yang, Szu-Chun, Tseng, Yau-Lin, Su, Po-Lan, Lin, Chien-Chung, Su, Wu-Chou
Publicado 2022

Cigarette smoke increases susceptibility of alveolar macrophages to SARS-CoV-2 infection through inducing reactive oxygen species-upregulated angiotensin-converting enzyme 2 expres...

por Kuo, Chin-Wei, Su, Po-Lan, Huang, Tang-Hsiu, Lin, Chien-Chung, Chen, Chian-Wei, Tsai, Jeng-Shiuan, Liao, Xin-Min, Chan, Tzu-Yi, Shieh, Chi-Chang
Publicado 2023

Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy

por Chen, Chian-Wei, Lin, Chien-Yu, Tsai, Jeng-Shiuan, Lin, Chia-Yin, Chang, Chao-Chun, Yen, Yi-Ting, Tseng, Yau-Lin, Su, Po-Lan, Lin, Chien-Chung
Publicado 2023

Chemotherapy outcomes in EGFR‐TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study

por Lin, Chien‐Yu, Hu, Chia‐Hao, Hsu, Chia‐Fu, Tsai, Jeng‐Shiuan, Chen, Chian‐Wei, Lin, Chia‐Yin, Chang, Chao‐Chun, Yen, Yi‐Ting, Tseng, Yau‐Lin, Su, Po‐Lan, Lin, Chien‐Chung
Publicado 2023

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors

por Wang, Sheng‐Yuan, Lai, Ching‐Han, Chen, Chian‐Wei, Yang, Szu‐Chun, Chang, Chao‐Chun, Lin, Chia‐Ying, Yen, Yi‐Ting, Tseng, Yau‐Lin, Su, Po‐Lan, Lin, Chien‐Chung, Su, Wu‐Chou
Publicado 2021

Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs

por Chu, Chang-Yao, Lin, Chien-Yu, Lin, Chien-Chung, Li, Chien-Feng, Wu, Shang-Yin, Tsai, Jeng-Shiuan, Yang, Szu-Chun, Chen, Chian-Wei, Lin, Chia-Yin, Chang, Chao-Chun, Yen, Yi-Ting, Tseng, Yau-Lin, Su, Po-Lan, Su, Wu-Chou
Publicado 2023

The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy

por Su, Po-Lan, Chen, Jung-Yueh, Chu, Chang-Yao, Chen, Yi-Lin, Chen, Wan-Li, Lin, Kuan-Yu, Ho, Chung-Liang, Tsai, Jeng-Shiuan, Yang, Szu-Chun, Chen, Chian-Wei, Wu, Yi-Lin, Tseng, Yau-Lin, Chang, Chao-Chun, Yen, Yi-Ting, Lin, Chia-Ying, Lin, Chien-Chung, Su, Wu-Chou
Publicado 2022